Skip to content

Evaluation of Anti hyperglycemic Effect of internal septum of Juglans regia in patients with diabetes mellitus type II: A Double blind Randomized Clinical Trial

Primary Evaluation of Anti hyperglycemic Effect of internal septum of Juglans regia in patients with diabetes mellitus type II: A Double blind Randomized Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201229049877N1
Enrollment
60
Registered
2021-02-06
Start date
2021-04-04
Completion date
Unknown
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus without complications

Interventions

Intervention 1: Intervention group: in this group, each patient will receive a capsule containing lyophilized powder of hydroalcoholic extract of internal septum of walnut (J. regia) three times a day

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Obtain consent from patients Age between 25 and 70 year old HbA1C=7% and less than 9% and FPG = 130-250 mg / dl Take metformin and/or other anti-diabetic agents (in maximum and constant dose for three months) or metformin alone (in maximum and constant dose for three months) Constant diet and physical activity during the study (according to a questionnaire translated and validated into Persian) The patient's anti-diabetic medication regimen remained constant during the study No allergies to walnuts

Exclusion criteria

Exclusion criteria: History of walnut allergy Immune system defects Pregnancy and lactation Cardiovascular disease (coronary artery ischemia, EF <45%) Take medications that change blood glucose levels (corticosteroids, tacrolimus, anti-AIDS drugs, antipsychotic drugs) Uncontrolled thyroid disease Acute infection History of diabetic ketoacidosis eGFR<60 ml/min Acute hepatitis (increase in ALT and AST to more than 10 to 20 times normal) cirrhosis Proliferative retinopathy Severe weight loss (at least 10% over 6 months) Consumption of any other medicine and herbal products, including walnuts

Design outcomes

Primary

MeasureTime frame
Decreases of hemogllubin A1C (HbA1C)c. Timepoint: 0 and 12 weeks after initiation of the drug. Method of measurement: serum level measurement.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoha Namazi

Tehran University of Medical Sciences

namazisoha@yahoo.com+98 21 6658 1692

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026